The Utility of Noninvasive serologic markers in the management of early allograft rejection in liver transplantation recipients

Rolland Dickson, Gregory Y. Lauwers, Charles B. Rosen, Rachel Cantwell, David R. Nelson, Johnson Y.N. Lau

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background. Early allograft rejection after orthotopic liver transplantation (OLT) currently requires a biopsy for diagnosis. Alpha- glutathione S-transferase (α-GST) and Pi-glutathione S-transferase (Pi-GST) are potential noninvasive markers of hepatocyte and biliary epithelial cell injury. Our aim was to determine the utility of noninvasive serologic markers in the management of early hepatic allograft rejection. Methods. Forty-four of 52 consecutive adult patients undergoing primary OLT at the University of Florida were included in the study. All had protocol liver biopsies between days 6 and 8 after OLT. Serum α-GST and plasma Pi-GST were determined using a sandwich enzyme immunoassay (Biotrin International, Dublin, Ireland). All biopsy specimens were retrospectively reviewed and scored for rejection and cholestasis. Results. The biopsy specimens were scored for rejection as moderate to severe in 14 patients (group 1) or none to mild in 30 patients (group 2). Group 1 had statistically higher mean levels than group 2 for α- GST on days 6, 7, and 9; alanine aminotransferase on days 6 and 9; aspartate aminotransferase (AST) on days 6 and 7; alkaline phosphate (AP) on days 3 through 7, 9, and 10; and γ-glutamyl transferase on day 3. No differences between groups were seen with Pi-GST or total bilirubin. Between days 6 and 8, the following values were found more frequently in group 1 than group 2: α-GST level >15 ng/ml (11/14 vs. 14/30; P<0.01); AST >100 U/L (8/14 vs. 2/30; P=0.002); and AP >120 U/L (14/14 vs. 17/30). Combining AP with either α-GST or AST led to improved detection of rejection over any single marker alone. In the first week after the initiation of rejection treatment, α-GST was the only marker that accurately predicted response. Conclusion. Serum α- GST may be useful in the management of early hepatic allograft rejection. A combination of noninvasive markers may be beneficial to diagnose early hepatic allograft rejection.

Original languageEnglish (US)
Pages (from-to)247-253
Number of pages7
JournalTransplantation
Volume68
Issue number2
DOIs
StatePublished - Jul 27 1999

Fingerprint

Glutathione S-Transferase pi
Liver Transplantation
Allografts
Biopsy
Liver
Phosphates
Aspartate Aminotransferases
Cholestasis
Transferases
Glutathione Transferase
Serum
Alanine Transaminase
Immunoenzyme Techniques
Ireland
Bilirubin
Hepatocytes
Epithelial Cells
Wounds and Injuries
Therapeutics

ASJC Scopus subject areas

  • Transplantation

Cite this

The Utility of Noninvasive serologic markers in the management of early allograft rejection in liver transplantation recipients. / Dickson, Rolland; Lauwers, Gregory Y.; Rosen, Charles B.; Cantwell, Rachel; Nelson, David R.; Lau, Johnson Y.N.

In: Transplantation, Vol. 68, No. 2, 27.07.1999, p. 247-253.

Research output: Contribution to journalArticle

Dickson, Rolland ; Lauwers, Gregory Y. ; Rosen, Charles B. ; Cantwell, Rachel ; Nelson, David R. ; Lau, Johnson Y.N. / The Utility of Noninvasive serologic markers in the management of early allograft rejection in liver transplantation recipients. In: Transplantation. 1999 ; Vol. 68, No. 2. pp. 247-253.
@article{1142c9d9846b4b51ad9965d61175b9dd,
title = "The Utility of Noninvasive serologic markers in the management of early allograft rejection in liver transplantation recipients",
abstract = "Background. Early allograft rejection after orthotopic liver transplantation (OLT) currently requires a biopsy for diagnosis. Alpha- glutathione S-transferase (α-GST) and Pi-glutathione S-transferase (Pi-GST) are potential noninvasive markers of hepatocyte and biliary epithelial cell injury. Our aim was to determine the utility of noninvasive serologic markers in the management of early hepatic allograft rejection. Methods. Forty-four of 52 consecutive adult patients undergoing primary OLT at the University of Florida were included in the study. All had protocol liver biopsies between days 6 and 8 after OLT. Serum α-GST and plasma Pi-GST were determined using a sandwich enzyme immunoassay (Biotrin International, Dublin, Ireland). All biopsy specimens were retrospectively reviewed and scored for rejection and cholestasis. Results. The biopsy specimens were scored for rejection as moderate to severe in 14 patients (group 1) or none to mild in 30 patients (group 2). Group 1 had statistically higher mean levels than group 2 for α- GST on days 6, 7, and 9; alanine aminotransferase on days 6 and 9; aspartate aminotransferase (AST) on days 6 and 7; alkaline phosphate (AP) on days 3 through 7, 9, and 10; and γ-glutamyl transferase on day 3. No differences between groups were seen with Pi-GST or total bilirubin. Between days 6 and 8, the following values were found more frequently in group 1 than group 2: α-GST level >15 ng/ml (11/14 vs. 14/30; P<0.01); AST >100 U/L (8/14 vs. 2/30; P=0.002); and AP >120 U/L (14/14 vs. 17/30). Combining AP with either α-GST or AST led to improved detection of rejection over any single marker alone. In the first week after the initiation of rejection treatment, α-GST was the only marker that accurately predicted response. Conclusion. Serum α- GST may be useful in the management of early hepatic allograft rejection. A combination of noninvasive markers may be beneficial to diagnose early hepatic allograft rejection.",
author = "Rolland Dickson and Lauwers, {Gregory Y.} and Rosen, {Charles B.} and Rachel Cantwell and Nelson, {David R.} and Lau, {Johnson Y.N.}",
year = "1999",
month = "7",
day = "27",
doi = "10.1097/00007890-199907270-00015",
language = "English (US)",
volume = "68",
pages = "247--253",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - The Utility of Noninvasive serologic markers in the management of early allograft rejection in liver transplantation recipients

AU - Dickson, Rolland

AU - Lauwers, Gregory Y.

AU - Rosen, Charles B.

AU - Cantwell, Rachel

AU - Nelson, David R.

AU - Lau, Johnson Y.N.

PY - 1999/7/27

Y1 - 1999/7/27

N2 - Background. Early allograft rejection after orthotopic liver transplantation (OLT) currently requires a biopsy for diagnosis. Alpha- glutathione S-transferase (α-GST) and Pi-glutathione S-transferase (Pi-GST) are potential noninvasive markers of hepatocyte and biliary epithelial cell injury. Our aim was to determine the utility of noninvasive serologic markers in the management of early hepatic allograft rejection. Methods. Forty-four of 52 consecutive adult patients undergoing primary OLT at the University of Florida were included in the study. All had protocol liver biopsies between days 6 and 8 after OLT. Serum α-GST and plasma Pi-GST were determined using a sandwich enzyme immunoassay (Biotrin International, Dublin, Ireland). All biopsy specimens were retrospectively reviewed and scored for rejection and cholestasis. Results. The biopsy specimens were scored for rejection as moderate to severe in 14 patients (group 1) or none to mild in 30 patients (group 2). Group 1 had statistically higher mean levels than group 2 for α- GST on days 6, 7, and 9; alanine aminotransferase on days 6 and 9; aspartate aminotransferase (AST) on days 6 and 7; alkaline phosphate (AP) on days 3 through 7, 9, and 10; and γ-glutamyl transferase on day 3. No differences between groups were seen with Pi-GST or total bilirubin. Between days 6 and 8, the following values were found more frequently in group 1 than group 2: α-GST level >15 ng/ml (11/14 vs. 14/30; P<0.01); AST >100 U/L (8/14 vs. 2/30; P=0.002); and AP >120 U/L (14/14 vs. 17/30). Combining AP with either α-GST or AST led to improved detection of rejection over any single marker alone. In the first week after the initiation of rejection treatment, α-GST was the only marker that accurately predicted response. Conclusion. Serum α- GST may be useful in the management of early hepatic allograft rejection. A combination of noninvasive markers may be beneficial to diagnose early hepatic allograft rejection.

AB - Background. Early allograft rejection after orthotopic liver transplantation (OLT) currently requires a biopsy for diagnosis. Alpha- glutathione S-transferase (α-GST) and Pi-glutathione S-transferase (Pi-GST) are potential noninvasive markers of hepatocyte and biliary epithelial cell injury. Our aim was to determine the utility of noninvasive serologic markers in the management of early hepatic allograft rejection. Methods. Forty-four of 52 consecutive adult patients undergoing primary OLT at the University of Florida were included in the study. All had protocol liver biopsies between days 6 and 8 after OLT. Serum α-GST and plasma Pi-GST were determined using a sandwich enzyme immunoassay (Biotrin International, Dublin, Ireland). All biopsy specimens were retrospectively reviewed and scored for rejection and cholestasis. Results. The biopsy specimens were scored for rejection as moderate to severe in 14 patients (group 1) or none to mild in 30 patients (group 2). Group 1 had statistically higher mean levels than group 2 for α- GST on days 6, 7, and 9; alanine aminotransferase on days 6 and 9; aspartate aminotransferase (AST) on days 6 and 7; alkaline phosphate (AP) on days 3 through 7, 9, and 10; and γ-glutamyl transferase on day 3. No differences between groups were seen with Pi-GST or total bilirubin. Between days 6 and 8, the following values were found more frequently in group 1 than group 2: α-GST level >15 ng/ml (11/14 vs. 14/30; P<0.01); AST >100 U/L (8/14 vs. 2/30; P=0.002); and AP >120 U/L (14/14 vs. 17/30). Combining AP with either α-GST or AST led to improved detection of rejection over any single marker alone. In the first week after the initiation of rejection treatment, α-GST was the only marker that accurately predicted response. Conclusion. Serum α- GST may be useful in the management of early hepatic allograft rejection. A combination of noninvasive markers may be beneficial to diagnose early hepatic allograft rejection.

UR - http://www.scopus.com/inward/record.url?scp=0033609441&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033609441&partnerID=8YFLogxK

U2 - 10.1097/00007890-199907270-00015

DO - 10.1097/00007890-199907270-00015

M3 - Article

C2 - 10440396

AN - SCOPUS:0033609441

VL - 68

SP - 247

EP - 253

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 2

ER -